• Novel mechanistic role for a specific N-linked glycan on APC in regulating PAR1 proteolysis • First description of an APC variant with enhanced therapeutic cytoprotective activity in vivo Abstract Activated protein C (APC) is an anticoagulant protease that initiates cell signaling via protease-activated receptor 1 (PAR1) to regulate vascular integrity and inflammatory response. In this study, a recombinant APC variant (APC N329Q ) mimicking the naturally occurring APC-β plasma glycoform was found to exhibit superior PAR1 proteolysis at a cleavage site that selectively mediates cytoprotective signaling. APC N329Q also enhanced integrin α M β 2 -dependent PAR1 proteolysis to exert significantly improved antiinflammatory activity on macrophages compared to wild type APC. Recent therapeutic applications of recombinant APC in ischemic stroke models have utilized APC variants with limited anticoagulant activity to negate potential bleeding side-effects. Using a mouse model of ischemic stroke and late t-PA intervention, the neuroprotective activity of a murine APC variant with limited anticoagulant activity (mAPC PS ) was compared to an identical APC variant except for the absence of glycosylation at the APC-β sequon (mAPC PS/N329Q ). Remarkably, mAPC PS/N329Q limited cerebral ischemic injury and reduced brain lesion volume significantly more effectively than mAPC PS . Collectively, this study reveals the importance of APC glycosylation in controlling the efficacy of PAR1 proteolysis by APC and demonstrates the potential of novel APC variants with superior For personal use only. on October 28, 2017. by guest www.bloodjournal.org From cytoprotective signaling function as enhanced therapeutic agents for the treatment of ischemic stroke.
Introduction
Activated protein C (APC) plays multiple regulatory roles that cumulatively serve to limit thrombus development 1 and attenuate inflammation 2 . APC engagement with the endothelial cell protein C receptor (EPCR) facilitates proteolysis-dependent activation of protease-activated receptor 1 (PAR1) 3 , which protects the endothelial cell barrier from disruptive agents 4 , inhibits apoptosis 5, 6 and limits cytokine expression from cells exposed to pro-inflammatory stimuli 6, 7 .
Recombinant APC signaling attenuates neurovascular sequelae associated with experimental murine ischemic stroke [8] [9] [10] and limits neurotoxicity due to subsequent thrombolytic tissue plasminogen activator (t-PA) administration. 11, 12 Recombinant APC therefore represents a promising neuroprotective drug candidate to treat ischemic stroke and a recombinant non-anticoagulant APC variant is currently being evaluated as an adjunctive therapy to minimize the adverse effects of t-PA administration 13, 14 .
A recombinant APC variant (APC N329Q ) that mimics the glycosylation pattern of the endogenous plasma APC-β glycoform 15 exhibits significantly enhanced PAR1dependent cytoprotective activity on endothelial cells compared to wild type APC 16 . In this study, we sought to determine the molecular basis for superior APC-β cytoprotective signaling and establish whether ablation of the APC-β glycosylation For personal use only. on October 28, 2017. by guest www.bloodjournal.org From sequon to accelerate cytoprotective signaling represents a novel means by which to increase the therapeutic efficacy of APC in an ischemic stroke model.
Methods

Materials
A complete description of the reagents used in this study is included in 'Supplementary Material'.
Preparation of recombinant APC
Recombinant human and murine wild type protein C and variants were generated, expressed and purified largely as previously described. 16, 17 A detailed description is provided in 'Supplementary Material'.
Detection of PAR1 proteolysis on HEK 293T cells
PAR1 reporter-transfected 293T cells were incubated with APC in serum-free DMEM supplemented with 3mM CaCl 2 and 0.6mM MgCl 2 for 3 hours, after which the supernatant was removed and AP activity measured using an AP substrate (QUANTI-Blue, Invivogen) at 650nm.
APC inhibition of cytokine secretion from LPS-stimulated macrophages
Analysis of APC inhibition of cytokine secretion from RAW264.7 cells was performed as previously described 18 . TNFα and IL-6 were measured by ELISA (R&D Systems).
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Mouse model of ischemic stroke
Ischemic stroke in mice was induced as previously described 19 and further detailed in 'Supplementary Materials'. Briefly, 200µl of 10mg/kg t-PA (10% bolus, 90% perfusion during 20 minutes) with or without 0.2mg/kg mAPC PS or mAPC PS/N329Q (50% bolus, 50% perfusion during 20 minutes) were given intravenously 3 hours after vessel occlusion.
After 24 hours, mice were euthanized and brains removed and frozen in isopentane.
20μm cryostat-cut coronal brain sections were stained with thionine and analyzed (Image J 1.48V). For volume analysis, one section out of every 10 was stained covering the entire lesion, and lesion (unstained) areas were measured.
Results & Discussion
We hypothesized that enhanced cytoprotective PAR1 signaling by APC-β was a consequence of accelerated EPCR-dependent PAR1 proteolysis. To test this, 293T Generation of unique tethered ligands by APC or thrombin, due to distinct cleavage events at Arg-46 or Arg-41 respectively on PAR1, has been proposed as a potential mechanism to explain the disparate outcomes of PAR1 signaling initiated by each protease 21, 22 . To determine whether the enhanced cytoprotective activity exhibited by For personal use only. on October 28, 2017. by guest www.bloodjournal.org From APC N329Q was a consequence of enhanced PAR1 proteolysis at the non-canonical Arg-46 cleavage site, 293T cells were co-transfected with EPCR and either PAR1 R41Q -AP or PAR1 R46Q -AP reporter variants (Figure 1b and 1c) . Notably, cleavage at the Arg-46 site on PAR1 was especially sensitive to loss of N-linked glycosylation following PNGase F treatment and particularly loss of glycosylation at the APC-β sequon (Figure 1b) . In contrast, Arg-41 proteolysis was limited in the presence of APC, and largely insensitive to glycosylation status (Figure 1c ). The increased rate of Arg-46 proteolysis on PAR1 by APC PNG and APC N329Q provides a novel molecular explanation for the enhanced cytoprotective activity of APC N329Q on endothelial cells and supports the emerging concept of biased PAR1 agonism to achieve downstream cytoprotective signaling. Thrombolysis with t-PA is the only FDA-approved thrombolytic treatment for ischemic stroke, but can only be safely administered within 3 hours of symptom onset due to significant neurotoxicity 24 . Recombinant APC variants with severely attenuated anticoagulant activity reduce t-PA-associated toxicity in murine models of ischemic stroke in a PAR1-dependent manner 11, 12 . We hypothesized that a recombinant nonanticoagulant APC that consists solely in the β -glycoform would be more efficacious in reducing t-PA neurotoxicity than existing APC variants in a murine model of ischemic stroke with late t-PA intervention. Similar to its human equivalent, in vitro analysis indicated that loss of N-linked glycan attachment at Asn-329 in murine APC (mAPC N329Q ) enhanced PAR1 proteolytic and anti-inflammatory activity (Figure 2a (Figure 2d & 2e) . As anticipated, sham-operated mice did not develop cerebral injury ( Supplementary Figure 2) . Like other mAPC variants with reduced anticoagulant activity 12 , mAPC PS retained the ability to reduce t-PA-induced cerebral injury 24 hours after stroke and t-PA administration, albeit modestly in this model (Figure 2f & 2g) . mAPC PS/N329Q , however, significantly reduced brain lesion size is composed solely of the APCβ fraction. (f) Brain infarct volumes post-stroke and t-PA administration were calculated in each mouse by staining 20μm coronal brain sections with thionine, which is unable to stain lesion areas. For volume analysis, one section of every 10 covering the entire lesion was analyzed. Individual values and the median of each group are represented. n=9-15; *p=0.006, **p=0.004. (g) Images corresponding to two thionine-stained sections of representative mice from each group are shown. Lesion areas are unstained, whereas remaining healthy tissue is stained purple.
